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nnate immunity is the first line of host defense and is primarily initiated via the activation of germ line-encoded pattern-recognition receptor (PRR)-mediated innate immune signaling. 1 Although many innate immune mechanisms have been identified, integrated knowledge of the function and regulation of innate immune signaling remains in its infancy. Evolutionary evidence reveals that Toll-like receptors (TLRs), retinoic acid-inducible gene I-like receptors (RLRs), and their adaptor genes are conserved in jawless vertebrates; however, IRF3, IRF7, type I IFN, and inflammatory cytokine genes, such as TNF-α, IL-12p40, and IL-6, do not exist in jawless vertebrates. 2 These observations imply that the TLR-and RLRmediated conventional innate immune signaling pathways are incomplete in jawless vertebrates, and the molecular basis of the innate immune system in jawless vertebrates may be distinct from that of jawed vertebrates. Therefore, these evidences raise the following questions: What is the function of preexisting innate immune signaling? If it can perform host defense functions, what is the mechanism? If not, the preexisting signaling may perform nonimmune functions because of the lack of certain transcription factors and cytokine genes.
Innate immune response pathways and cardiometabolic pathways are evolutionarily conserved throughout species and are fundamental for survival. 3 Therefore, cardiometabolic regulation and immune responses are intimately integrated and functionally dependent. 4 In addition to the activation of immune cells, innate immune signaling also affects the function of nonimmune cells in metabolic organs and the cardiovascular system, thus influencing the development of cardiometabolic disease (CMD), a common and complex disorder that involves a cluster of symptoms, including obesity, insulin resistance, diabetes mellitus, hypertension, dyslipidemia, hepatic steatosis, atherosclerosis, ischemic heart diseases, and cardiac hypertrophy and fibrosis. 5 Importantly, these signals may act not only by immune-dependent manners but also by immuneindependent mechanisms, with the latter transducing the signals toward pathways that are different from these in conventional innate immune responses. [6] [7] [8] [9] [10] These reprogrammed innate immune signaling events (here, innate immune signaling mainly refers to certain parts of intact PPR-mediated immune signaling) have recently emerged as central orchestrators of cardiovascular and metabolic functions in health and disease. Remarkably, both aberrantly high abrogation and activation of these signals in different tissues contribute to the development of CMD, indicating the importance of a finely balanced signaling cascade. In this review, we summarize the canonical innate immune signaling of immune responses and provide an update on reprogrammed innate immune signaling in response to cardiovascular and metabolic stresses.
Canonical Innate Immune Signaling
PRRs have evolved to recognize conserved microbial structures indicative of the presence of bacteria, viruses, fungi, or parasites. 3 Mammalian PRRs can be divided into 2 classes: membrane-bound and cytosolic. The former includes TLRs and C-type lectin receptor, while the latter comprises RLRs, nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), and absent in melanoma 2 (AIM2)-like receptors (ALRs); all of which mediate canonical innate immune signaling for host defense. 
TLR-Mediated Innate Immune Signaling
Activated TLRs undergo homo-or heterophilic dimerization and then induce myeloid differentiation primary response protein 88 (MyD88)-dependent (all TLRs, except TLR3) or TIR domain-containing adapter-inducing interferon-β (TRIF)-dependent (TLR3 and TLR4) signaling pathways. Herein, we take cell surface TLR4-MyD88 and endosomal TLR3-TRIF signaling as examples ( Figure 1A ). In TLR4-MyD88-dependent signaling, TLR4 recruits TRAF6 (TNF receptor associated factor 6) via MyD88-IRAK4/1/2. TRAF6, an E3 ubiquitin ligase, catalyzes the attachment of K63-linked polyubiquitin chains onto its substrates, including itself, TAK1 (transforming growth factor-beta-activated kinase 1) binding protein (TAB) 2/3 and nuclear factor (NF)-κB essential modulator (NEMO), and synthesizes free, unanchored K63-polyubiquitin chains. [11] [12] [13] Ubiquitinated TRAF6 recruits and activates the TAK1-TAB1/2/3 complex by binding to TAB2; TAK1, in turn, phosphorylates inhibitor of NF-κB kinase subunit-β (IKKβ) and activates IKKs-NF-κB signaling. 13 Moreover, the degradative ubiquitination of MyD88-bound TRAF3 permits the release of the MyD88-associated signaling complex into the cytosol to activate mitogen-activated protein kinase signaling.
14 In TLR3-TRIF-dependent signaling, TRAF3 associates with TRIF and IRAK1 and triggers TRAF3 self-ubiquitination via noncanonical K63-linked polyubiquitination; activated TRAF3 then interacts with the TBK1 (TANK-binding kinase 1)-binding proteins, DOK3 (docking protein 3), and APPL1 (adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1) to recruit TBK1/IKKε, thereby inducing the TBK1/IKKε-mediated phosphorylation of interferon regulatory factor (IRF) 3/7.
14,15 TRIF also interacts with TRAF6 or receptorinteracting protein 1, followed by the recruitment of TAB2 and TAK1 for NF-κB activation. 16, 17 Therefore, the primary signaling downstream of TLR can be summarized as TRAF6-TAK1-NF-κB and TRAF3-TBK1-IRF3/7.
C-Type Lectin Receptor-Mediated Innate Immune Signaling
Similar to TLRs, C-type lectin receptors, such as dectin-1 and dectin-2, are second type of membrane-bound PRRs ( Figure 1B) . On ligand engagement, dectin-1 transduces signals directly to spleen tyrosine kinase via its immunoreceptor tyrosine-based activation motif, whereas dectin-2 requires immunoreceptor tyrosine-based activation motif-bearing FcRγ (Fc receptor γ chain) as an adaptor. Subsequently, spleen tyrosine kinase transduces signals to protein kinase C-δ, which then activates CARD9 (caspase recruitment domain-containing protein 9)-B-cell lymphoma/leukemia 10-mucosa-associated lymphoid tissue lymphoma translocation protein 1 for the activation of TAK1-dependent NF-κB signaling. 18, 19 Moreover, activation of the Ras-GRF1 (Ras-guanine-nucleotide-releasing factor 1)-CARD9-H-Ras complex by spleen tyrosine kinase is indispensable for dectin-1-mediated extracellular signal-regulated kinase (ERK), but not NF-κB, activation.
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RLR-Mediated Innate Immune Signaling
In contrast to sensing viral RNA and DNA in the endosome by TLR, RLRs, including retinoic acid-inducible gene I, melanoma differentiation-associated gene 5, and laboratory of genetics and physiology 2, recognize viral RNA in the cytoplasm (Figure 2, left) . After viral RNA binding, the signaling domains (tandem CARDs or 2CARDs) of retinoic (Toll-interleukin 1 receptor [TIR] domaincontaining adaptor protein), MyD88 (myeloid differentiation primary response protein 88), IRAK4 (interleukin 1 receptor associated kinase 4), IRAK2, IRAK1, and TRAF6 (TNF receptor associated factor 6) to form the signaling complex that subsequently induces TGF (transforming growth factor)-TAK1 (beta activated kinase 1)-inhibitor of nuclear factor (NF)-κB kinase subunit (IKK)-mediated NF-κB activation. The separate MyD88-associated multiprotein complex is required for TAK1-mediated mitogen-activated protein kinase (MAPK) activation. After sensing viral nucleic acids, endosomal TLR3 directly recruits TRIF without TRAM and then induces TRAF3-TBK1-IRF3/7 signaling and TRAF6-TAK1-IKK-NF-κB signaling. B, Dectin-1 and Dectin-2 are C-type lectin receptors that recognize major carbohydrate structures in fungal cell walls. Dectin-1 senses β-glucans, whereas Dectin-2 recognizes α-mannans. Both Dectin-1 and Dectin-2 can activate NF-κB via the CARD9 (caspase recruitment domain-containing protein 9)/Bcl10 (B-cell lymphoma/leukemia 10)/Malt1 (mucosaassociated lymphoid tissue lymphoma translocation protein 1) complex. Moreover, Dectin-1 can induce extracellular signal-regulated kinase (ERK) activation through CARD9-bridged Ras-GRF1 (Ras-guanine-nucleotide-releasing factor 1)-H-Ras complex. NEMO indicates NF-κB essential modulator; FcRγ, Fc receptor γ chain; AP-1, activator protein-1; and TAB, TAK1 (transforming growth factor-betaactivated kinase 1) binding protein.
acid-inducible gene I and melanoma differentiation-associated gene 5 form homo-oligomers to bind to MAVS (mitochondrial antiviral signaling protein), and their interactions result in filament formation of MAVS, which is a prerequisite for downstream signal activation. 21 Liu et al 22 have reported that MAVS recruits and activates TRAF6, TRAF2, and TRAF5 rather than TRAF3. These E3 ligases, in turn, synthesize polyubiquitin chains for the recruitment of NEMO through its ubiquitinbinding domains, providing a platform for NEMO binding and, possibly, the further activation of NEMO-TBK1-IKKε/i-IRF3/7 and NEMO-IKKα-IKKβ-NF-κB signaling.
ALR-Mediated Innate Immune Signaling
ALRs, such as AIM2 and IFI16 (interferon gamma inducible protein 16), and other newly identified cytosolic DNA sensors, are responsible for sensing the viral DNA that is free in the cytoplasm (Figure 2 , middle and right). AIM2 and IFI16 recognize double-stranded DNA in the cytoplasm and Kaposi sarcoma-associated herpesvirus in the nucleus, respectively, and then recruit apoptosis-associated speck-like protein containing a CARD (ASC) and, subsequently, procaspase-1 to form inflammasomes (see details below). 23, 24 Moreover, stimulator of interferon genes can function both as a direct sensor of cyclic dinucleotides and as an adaptor for cytosolic DNA sensors. The activated stimulator of interferon genes rapidly translocates from the endoplasmic reticulum to the Golgi apparatus, where stimulator of interferon genes is palmitoylated, and finally assembles with TBK1 in cytoplasmic punctate structures to induce IRF3-mediated interferons (IFN) production. 25, 26 
NLR-Mediated Innate Immune Signaling
Another large cytosolic PRR family comprises the NLRs, which respond to various pathogen-associated molecular patterns derived from bacteria, viruses, fungi, and protozoa; self-derived damage-associated molecular patterns (ATP and cholesterol crystals); and environment-derived stimulants (alum, asbestos, etc). 27 NLRs can be divided into inflammasome-forming NLRs (NLRP1-3, NLRP6, NLRP7, NLRP12, NLRC4/5, and NLRB; Figure 3 , left) and noninflammasomeforming NLRs (NOD1, NOD2, NLRC3, NLRP10, NLRX1, and NLRA; Figure 3 , right). [28] [29] [30] For example, after sensing ligands, NLRP3/6/12 interact with ASC; ASC then associates with procaspase-1 to form inflammasomes, which serve as scaffolds to recruit the inactive zymogen procaspase-1.
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Oligomerization of procaspase-1 induces its autoproteolytic cleavage into active caspase-1, which is a cysteine-dependent protease that cleaves the precursor cytokines prointerleukin (pro-IL)-1β and pro-IL-18, generating biologically active IL-1β and IL-18, respectively. 31 Moreover, active caspase-1 can also induce the cleavage of gasdermin D, and cleaved gasdermin D induces pyroptosis and the secretion but not the proteolytic maturation of IL-1β. 32, 33 NOD1 and NOD2 interact with receptor-interacting protein 2 via CARD-CARD interactions. Activated receptor-interacting protein 2 transduces the signals to TAK1-IKKs-NF-κB, 34 TBK1-IRF5, 35 or JNK (c-Jun N-terminal kinase) and p38 for immune responses. 36, 37 Thus, pathogen-associated molecular patterns and damage-associated molecular patterns engage their corresponding PRRs and then transduce the signal to downstream adaptors and kinases, ultimately activating transcription factors, such as IRF, NF-κB, and AP-1 (activator protein-1). Then, the activated cells produce a set of cytokines, including antiviral type I IFNs, proinflammatory cytokines, and chemokines, that interacting with their corresponding receptors to orchestrate the next phase of host defense. 1, 38 However, sustained, excessive activation or inhibition of innate immune signaling is deleterious to the homeostasis of the affected tissues and system, and the cardiometabolic system is one of these vulnerable targets, as discussed below.
Reprogrammed Innate Immune Signaling in CMD
In addition to pathogens, cardiometabolic-associated danger signals, such as neurohumoral activation, hemodynamic overloading, shear stress, ischemia, hypoxia, and a high-fat diet (HFD), can activate canonical PRR-mediated innate immune signaling pathways and thereby influence the development of CMD, which has been comprehensively reviewed elsewhere. 4, [39] [40] [41] However, the roles of innate immune signaling in CMD extend far beyond what was previously believed. Innate immune signaling does not only serve to regulate immune cell activities. Indeed, innate immune signaling has also been found in the parenchymal cells of the heart, blood vessels, liver, fat, and muscle and thus influences CMD independent of conventional immune function. In this section, we will summarize in detail these nonconventional pathways, from PRRs, adaptors, and kinases to transcription factors, in the context of CMD.
PRR-Gut Microbiota Axis in Metabolic Diseases
Clearly, the microbiota strongly affects the innate immune system via its engagement with PRRs. Importantly, PRRs and their downstream components also play a key role in controlling the composition of the intestinal microbiota, which is essential for maintaining metabolic homeostasis and influencing metabolic disease. 42 Vijay-Kumar et al 43 have reported that the composition of the bacterial communities in the intestine is altered in TLR5-deficient mice ( Figure 4A ). These alterations in gut microbiota resulting from the loss of TLR5 in intestinal epithelial cells, rather than in dendritic cells, promote the development of obesity, hyperlipidemia, hypertension, and insulin resistance. In addition, these metabolic syndromes are exacerbated by HFD feeding. 43 -45 On a molecular level, the phenotype observed in these mice is linked to slightly increased food intake and absorption and to the induction of low-grade inflammation, which act both in association and independently. 43, 46 It is unclear how the altered gut microbiota initiates inflammation in TLR5-knockout mice and whether other TLRs mediate the effects of TLR5 deficiency. Therefore, TLR5/TLR4-double knockout mice, TLR5/TLR2-double knockout mice, and MyD88-knockout mice were used for further investigation. The results of these studies revealed that TLR5/TLR4-double knockout mice and TLR5/TLR2-double knockout mice still demonstrated features of metabolic syndrome. 43, 47 MyD88-knockout mice did not mimic the metabolic syndrome exhibited by TLR5-knockout mice, suggesting a potential role in metabolic syndrome for an TLR other than TLR2 and TLR4 and a role for cytokines, such as IL-1β and IL-18, whose levels are increased in noncolitic TLR5-knockout mice 48 and whose receptors signal in an MyD88-dependent manner. 43 However, another report indicated that MyD88-knockout mice display metabolic disturbances and increased bacterial translocation to mesenteric adipose tissue when fed a normal chow diet. 49 Considering that the gut microbiota is essential for the metabolic phenotype, this contradiction may be because of the mouse breeding environments. Recently, Singh et al 50 revealed that upregulation of hepatic stearoyl CoA desaturase 1 is also critical in gut microbiota-dependent metabolic syndrome in TLR5-knockout mice. TLR4 and TLR9, but not TLR5, are implicated in the NLRP3/6-inflammasomes-gut microbiota axis in metabolic diseases ( Figure 4A ). Henao-Mejia et al 52 revealed that mice genetically deficient in either the sensors (NLRP3 and NLRP6 but not NLRC4, NLRP12, or NLRP4c) or signaling components (ASC, caspase-1, and IL-18 but not IL-1R) of inflammasomes display enhanced methionine-choline-deficient diet-mediated nonalcoholic steatohepatitis (NASH). This worsening of NASH is driven by perturbing the normal gut microbial balance, resulting in the appearance of Prevotellaceae and a proportional increase in Porphyromonadaceae within the gut microflora. 51, 52 Interestingly, the exacerbation of NASH in these mice did not rely on hematopoietic or hepatocyte inflammasomes, implicating an alternate inflammasome-containing cell population, most likely epithelial cells, in controlling intestinal homeostasis. 51 To further investigate the underlying molecular mechanism, MyD8
, or TLR9 −/− mice were cohoused with inflammasome-deficient mice. This study revealed that microbial components, rather than whole organisms, were transmitted to the liver through the portal circulation, which triggered TLR4 and TLR9, but not TLR5, to induce hepatotoxic tumor necrosis factor-α production in the liver. 52, 53 Similar to inflammasome-forming NLRs, bacterial translocation was also regulated by noninflammasome-forming NOD1 and NOD2 in HFD-induced metabolic dysfunction ( Figure 4B ). NOD1-dependent translocation of Gram-negative bacteria into the mesenteric adipose tissue and blood initiates low-grade inflammation, which is essential for the early onset of HFD-induced diabetes mellitus. 49 In contrast to NOD1, NOD2 is required for gut mucosal bacterial colonization and depresses commensal bacterial translocation from the gut into the adipose tissue and liver. Therefore, NOD2-knockout mice exhibit greater amounts of adipose tissue and liver inflammation and exacerbated insulin resistance when fed an HFD. 54 Beyond the regulation of conventional innate immune responses, PRRs may regulate gut microbiota composition and thereby mediate metabolic disease. Although the mechanisms by which the innate immune system regulates pathogen clearance are clear, the precise mechanisms of PRR-mediated control of the microbiota composition remain largely unknown. It should be noted that mice residing in an environment with their excrement may exhibit increased transfer of gut microbiota relative to humans. 55 It is not known to what extent the cohabitation of adult humans promotes the transfer of their gut microbiota and influences health, such as metabolic status.
Inflammasome-Independent Role of NLRP3 in Cardiac Diseases
Although the normal activities of NLRP3/6 inflammasomes in maintaining the balance of intestinal microecology are essential for defense against NASH, an inflammasome-independent role for NLRP3 in heart diseases is emerging. NLRP3 is constitutively expressed in cardiac fibroblasts and is increased after transforming growth factor-β stimulation. The central nucleotide-binding domain of mitochondrial NLRP3 contributes to SMAD2 (SMAD family member 2) activation and nuclear translocation via increased mitochondrial reactive oxygen species production, thus inducing myofibroblast differentiation and cardiac fibrosis in response to transforming growth factor-β in vitro and angiotensin II in vivo 56 ( Figure  5A ). These results support a distinct role for NLRP3 in nonprofessional immune cells, independent of inflammasome formation, to regulate cardiac fibrosis. As in cardiac fibrosis, NLRP3 also displays inflammasome-independent function during cardiac ischemia/reperfusion (I/R) injury. Zuurbier et al 57 reported that ablation of NLRP3 abrogated ischemic preconditioning (IPC)-based protective effects on cardiac function and cardiac I/R-induced cell death and was associated with decreased IL-6/ STAT3 signaling ( Figure 5B ). Deficiency of the inflammasome adaptor ASC or IL-1 receptor inhibition did not alter the effect of IPC, whereas IL-6 neutralization using an antibody against IL-6 abrogated IPC in wild-type hearts. Thus, inflammasomeindependent mechanisms may be implicated in the protective effect of NLRP3 in IPC. It remains unclear how NLRP3 regulates IL-6 production when subjected to IPC. IL-18 has been reported to induce IL-6 expression. 58 However, authors of the study did not investigate IL-18 production in NLRP3 −/− hearts subjected to IPC. Moreover, ASC deficiency did not alter the effect of IPC; thus, the change in IL-6 content was likely not mediated by the NLRP3-inflammasome-dependent maturation of IL-18. Importantly, NLRP3 has been reported to function as a transcriptional regulator in T-helper 2 cells via binding and transactivating the IL-4 promoter in conjunction with IRF4.
59 IRF4 can induce IL-6 production in T cells and dendritic cells. 60, 61 Therefore, it is possible that NLRP3, in combination with IRF4, exerts transcriptional effects in inflammasome-independent functions to promote the protective effect of IPC. Similar to the protective effects of NLRP3 in IPC, Sandanger et al 62 reported that NLRP3 deficiency led to increased myocardial infarct size at 24 hours post-I/R without preconditioning. The same pattern was seen in ASC −/− mice although the difference between ASC −/− and wild-type mice was not statistically significant. Mechanistically, the absence of NLRP3 or ASC abolishes the function of a cardioprotective signaling pathway (Akt signaling) mediated by TLR2-induced preconditioning. 62 However, rather than using caspase-1 activity or mature IL-1β, the authors used IL-1β mRNA as a readout, which is not an acceptable measure of inflammasome activity. 63 In addition to its role in heart injury, NLRP3 also plays an inflammasome-independent role in animal models of kidney injury. 64, 65 These findings suggest a conserved role for NLRP3 in cardiac and renal injury that is independent of the formation of the canonical inflammasome and the maturation of cytokines by caspase-1 processing. This conserved, nonconventional signaling of NLRP3 might also influence the homeostasis of other target tissue. However, determining whether and how other NLRs influence CMD requires further investigation.
These nonprofessional signaling events mediated by the abovementioned PRRs, combined with evolutionary biological evidence, suggest that the signaling downstream of PRRs likely elicits nonimmune signaling and influences CMD development. Reprogrammed TRAF signaling, TAB-TAK1 and TBK1 signaling, and IRF signaling are discussed below.
TRAF Signaling in CMD
In immune response, TRAFs always function as critical E3 ligases downstream of TLR and RLR signaling. Similar to the PRRs above, TRAF signaling pathways can also be reprogrammed and participate in the pathogenesis of CMD ( Figure  6 ). Hepatic TRAF1 promotes hepatic steatosis by enhancing the activation of ASK1-mediated P38/JNK cascades. 66 Although there are no direct data to demonstrate that TRAF2 can influence hepatic steatosis, 1 study has indicated that hepatic TRAF2 directly promotes hepatic gluconeogenesis by promoting the hyperglycemic response (CREB [cAMP responsive element binding protein] phosphorylation) to Figure 5 . The inflammasome-independent role of NLRP3 in heart diseases. A, The canonical transforming growth factor (TGF)-β-SMAD2 (SMAD family member 2) signaling pathway is essential for fibrosis gene expression. Moreover, angiotensin II (ANG II) and TGF-β can activate mitochondrial NLRP3 to induce reactive oxygen species (ROS) production in mitochondria, which promotes SMAD2 phosphorylation, and combine with SMAD3 and SMAD4 to mediate cardiac fibrosis and myofibroblast differentiation. B, NLRP3 is essential for the protective effect of ischemic preconditioning (IPC) by promoting IL-6 production, possibly through its transcriptional activity. IL-6 binds to IL-6R and induces JAK and subsequent STAT3 activation, which translocates to the nucleus to induce genes expression involved in survival. I/R indicates ischemia/reperfusion. glucagon and to other factors that increase cAMP levels, thus leading to hyperglycemia without affecting insulin signaling during obesity. 67 In the heart, TRAF2 overexpression leads to spontaneous time-dependent cardiac remodeling that is associated with NF-κB and JNK activation 68 and enhanced pressure overload-induced cardiac hypertrophy and dysfunction via the activation of Akt/glycogen synthase kinase 3 β by an unknown mechanism. 69 By contrast, exogenous TRAF2 interacts with parkin RBR E3 ubiquitin protein ligase, reduces depolarized mitochondria by mitophagy, and rescues cell death in a cardiac myocyte I/R model. 70 These data indicate that the different stimuli determine the diverse functions of TRAF2 in the heart. TRAF3 promotes hypertensive cardiac remodeling by directly interacting with TBK1 in cardiomyocyte, which leads to TBK1 phosphorylation and downstream Akt activation. 71 This process is distinct from the canonical action of TRAF3 in TLR3 signaling, in which TRAF3 recruits TBK1 through DOK3 and APPL1. However, hepatic TRAF3 does not interact with TBK1 in response to a HFD; instead, it binds to TAK1 to induce TAK1 ubiquitination and subsequent autophosphorylation, thereby enhancing the activation of downstream IKKβ-NF-κB and MKK-JNK-IRS1 307 signaling cascades, while disrupting Akt-glycogen synthase kinase 3 β/forkhead box O1 signaling, all of which contribute to insulin resistance, glucose intolerance, and hepatic steatosis. 72, 73 In contrast to TRAF1, TRAF2, and TRAF3, TRAF5 is a negative regulator of CMD. Hepatic TRAF5 targets JNK1, rather than JNK2, and thus negatively regulates HFD-induced obesity, inflammation, insulin resistance, hepatic steatosis, and fibrosis. 74 TRAF5 deletion accelerates atherogenesis in mice by increasing inflammatory cell recruitment to the vessel wall and promoting foam cell formation. 75 Mechanistically, the enhanced JNK phosphorylation in TRAF5-knockout endothelial cells and macrophages may mediate some of the observed effects. In cardiomyocytes, the antihypertrophic effect of TRAF5 is related to its inhibition on MEK1/2-ERK1/2 signaling and NF-κB-dependent inflammatory responses. 76 Therefore, unlike canonical TRAF5-NEMO-TBK1-IRF3/7 or TRAF5-NEMO-IKKs-NF-κB signaling in RLR signaling, there is cell type-specific TRAF5-dependent inhibition of mitogen-activated protein kinase and NF-κB in CMD.
TRAF6 has been extensively studied in cardiovascular diseases. In response to various prohypertrophic stimuli, the activation of nicotinamide adenine dinucleotide phosphate oxidase and the production of ROS trigger TRAF6 autoubiquitination, which recruits TAB2 and promotes the formation of a TAK1 activation complex, enhancing the directly binding of TRAF6 to TAK1. 77 TRAF6-TAK1 interaction promotes TAK1 ubiquitination and phosphorylation, which are indispensable for TRAF6-mediated cardiac hypertrophic responses. The vascular functions of TRAF6 have been investigated in myeloid cells, endothelial cells, and vascular smooth muscle cells (VSMCs). The myeloid TRAF6-CD40 interaction is essential for the development of atherosclerosis and the formation of neointima. 78 However, the effects of endothelial TRAF6 in atherosclerosis are dependent on the sex. Endothelial TRAF6 deficiency in female ApoE −/− mice diminishes atherosclerosis by blocking NF-κB-dependent proinflammatory gene expression and monocyte adhesion to endothelial cells, whereas endothelial-specific TRAF6 deficiency has no effect on the development of atherosclerosis in male mice. 79 In VSMCs, classical TRAF6-TAK1-mediated NF-κB signaling is implicated in angiotensin II-induced inflammation responses 80 and neointima formation. 81 Moreover, TRAF6-induced K63-linked ubiquitination of smooth muscle protein 22-α facilitates the interaction of smooth muscle protein 22-α Figure 6 . Reprogrammed TRAF signaling in cardiovascular and liver diseases. The canonical TRAF signaling pathway primarily includes TRAF3-TANK-binding kinase 1 (TBK1)-interferon regulatory factor (IRF) 3/7 signaling, TRAF6-TAK1 (transforming growth factor-betaactivated kinase 1)-inhibitor of nuclear factor (NF)-κB kinase subunit (IKK)-NF-κB signaling, and CD40-TRAF6 signaling. However, TRAF signaling, not limited to TRAF3/6 signaling, can be reprogrammed under various cardiometabolic stresses. CREB indicates cAMP responsive element binding protein; ERK, extracellular signal-regulated kinase; G6Pase, glucose 6-phosphatase; G6PD, glucose-6-phosphate dehydrogenase; Hepatic GNG, Hepatic gluconeogenesis; HFD, high-fat diet; I/R, ischemia/reperfusion; JNK, c-Jun N-terminal kinase; PARKIN, parkin RBR E3 ubiquitin protein ligase; PEPCK, phosphoenolpyruvate carboxykinase; PO, pressure overload; SM22α, smooth muscle protein 22-α; and VSMCs, vascular smooth muscle cells.
with glucose-6-phosphate dehydrogenase, which subsequently mediates glucose-6-phosphate dehydrogenase membrane translocation and activation. This translocation and activation results in increased nicotinamide adenine dinucleotide phosphate generation via stimulation of the pentose phosphate pathway, which enhances VSMC viability and reduces apoptosis in vivo and in vitro via glutathione homeostasis. 82 Therefore, TRAF6 is both an E3 ligase that mediates TAK1 activation in innate immunity and smooth muscle protein 22-α activation in VSMCs, and this latter function is completely independent of immune responses. Future studies should investigate the different contributions of conventional and nonconventional TRAF6 signaling in vascular diseases, including determining which type of signaling is important and how the interaction between TRAF6 and its binding partners occurs.
TAB-TAK1 and TBK1-IKKε Signaling in CMD
In contrast to the conventional immunity-associated TAK1-TAB1/2/3 complex, which is formed and activated by the TRAF6-TAB2 interaction, in the cardiac context, TAB2 directly binds to regulator of calcineurin 1, recruiting TAK1, TAB1, and calcineurin and forming a macromolecular signaling complex. In this complex, TAK1 phosphorylates regulator of calcineurin 1 at serine 94 and 136, converting regulator of calcineurin 1 from an inhibitor to a facilitator of calcineurin-NF of activated T cells (NFAT) signaling and enhancing NFATc1 nuclear translocation and transcriptional activation for hypertrophic responses. In turn, calcineurin activation diminishes TAK1 signaling by dephosphorylating TAK1 and TAB1, thus establishing a negative feedback loop.
83 TAB1-mediated p38 autophosphorylation in cardiomyocytes has been described as a noncanonical mode of p38 activation and may serve as an important event leading to cardiac remodeling during ischemia or amyloidogenic light chain stimulation. 84 Therefore, TAB1/2 are not simply adaptors for TAK1-mediated IKKβ-NF-κB activation in innate immunity, the proremodeling effects of p38 and NFATc1 are also involved in the action of TAB1/2 in the heart. Unlike TAK1-mediated prohypertrophic signaling by TRAF6, TBK1 activation is essential for the prohypertrophic effect of TRAF3. Therefore, the suppressor of IKKɛ can directly interact with TBK1 to inhibit TBK1-Akt-mediated cardiac hypertrophy 85 (see details below). However, IKKε deficiency results in spontaneous cardiac hypertrophy, and the pathological change is aggravated after pressure overload via the activation of Akt/glycogen synthase kinase 3 β/mammalian target of rapamycin/forkhead box O and NF-κB signaling. 86 Although no studies have been conducted to determine the effect of suppressor of IKKɛ gene alterations on IKKɛ activity, these seemingly contradictory results indicate that the level of IKKɛ expression and activation influences its effects on cardiac hypertrophy. These noncanonical functions of TABs and TBK1 raised the following questions: What is the function of their downstream transcription factors in CMD? If these transcription factors act as essential regulator of CMD, is the mechanism via conventional immune signals or reprogrammed signaling?
IRF Signaling in CMD
Unlike the traditional transcription factor NF-κB, which acts as a key regulator of CMD by inducing immune and inflammatory responses, IRF family members function as stress sensors that influence CMD not only by the conventional immune targets but also by the reprogrammed IRF signaling pathways. In mice, cardiomyocyte inducible nitric oxide synthase overexpression results in peroxynitrite generation, heart block, and sudden death, whereas inducible nitric oxide synthase deficiency protects the heart from pressure overload-induced ventricular hypertrophy and congestive heart failure. 87, 88 Therefore, IRF1 induces a hypertrophic response via increasing inducible nitric oxide synthase transcription by binding to its promoter region. 89 In contrast, IRF1 limits neointima formation by promoting NO production and increasing the expression of the cyclindependent kinase inhibitor p21. 90 Moreover, IRF1 has been shown to repress adipogenesis by an unknown mechanism.
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IRF2 has been reported to transcriptionally activate VCAM-1 via binding to its promoter in muscle cells. 92 However, the function of IRF2 in CMD has not been clarified. Similar to IRF1, IRF3 also represses adipogenesis. 91 Hepatic IRF3 negatively regulates insulin resistance and steatosis by binding to the kinase domain of IKKβ to suppress IKKβ/NF-κB signaling. 93 In the cardiovascular system, IRF3 relieves hypertrophic responses by directly interacting with ERK2 to block ERK1/2 signaling 94 and represses VSMCs proliferation by associating with the AB domain of peroxisome proliferator-activated receptor (PPAR) γ in the nucleus. IRF3-bound PPARγ then binds to the PPAR response element region of the proliferating cell nuclear antigen gene, thereby negatively regulating its transcription. 95 Therefore, IRF1 and IRF2 act as transcription factors to regulate the expression of certain genes to mediate CMD development, whereas IRF3 has unique functional roles that go far beyond transcription factors.
The cardiometabolic effects of IRF4 have been extensively studied. CREB is an essential transcription factor that mediates cardiomyocyte and VSMC hypertrophy. [96] [97] [98] Cardiac IRF4 promotes hypertrophic responses via binding to the promoter region of CREB to increase its transcription. 99 In contrast, the expression of IRF4 in macrophages and regulatory T cells in adipose tissue has been implicated in the inhibition of obesity-associated inflammation, 100,101 which is a key contributor to insulin resistance. Forkhead box O1, which is phosphorylated and subsequently excluded from the nucleus on insulin stimulation, binds to the upstream flanking sequences of IRF4 to promote its expression. IRF4 contributes to lipolysis partly by inducing the expression of adipocyte triglyceride lipase and hormone-sensitive lipase, and IRF4 inhibits lipogenesis by blocking the expression of lipid biosynthetic genes. 102 Therefore, insulin's ability to increase lipid synthesis and decrease lipolysis in adipocytes is partly determined by inhibiting IRF4 expression. IRF4 also functions as a dominant transcriptional effector of thermogenesis in adipocytes. IRF4 induces the expression of PPARγ coactivator 1-α and PR/SET domain 16. Further, IRF4 physically interacts with the cofactor PPARγ coactivator 1 to drive the expression of uncoupling protein 1, which can dissociate O 2 consumption from ATP synthesis, a highly thermogenic process. 103 Thus, the obesityinhibiting effect of IRF4 in adipose tissue macrophages and visceral adipose tissue-regulatory T cells is immune signaling dependent, while IRF4 signaling is directly reprogrammed toward the regulation of metabolism in adipocytes. Moreover, IRF4 is highly expressed in the liver and skeletal muscle 99 ; however, its effects in these tissues remain under investigation.
In contrast to the beneficial effects of IRF4, IRF5 is a positive regulator of insulin resistance. IRF5 deficiency in macrophages, but not in adipocytes, promotes beneficial subcutaneous white adipose tissue expansion and insulin sensitivity in obesity. 104 The function of IRF6 in CMD remains unclear. IRF7-driven inflammatory network genes are more likely to be associated with susceptibility to type 1 diabetes mellitus 105 ; moreover, IRF7 contributes to HFD-induced inflammatory responses, insulin resistance and hepatic steatosis via increasing NF-κB activation. 106 In contrast, IRF7 negatively regulates cardiovascular remodeling by associating directly with IKKβ, thereby masking the IKKβ kinase domain in cardiomyocyte, 107 and by interacting with activating transcription factor 3 to inhibit the activating transcription factor 3-mediated induction of proliferating cell nuclear antigen transcription in VSMC. 108 Compared with the consistent role of IRF7 in both cardiac and vascular remodeling, IRF8 has adverse function in cardiac hypertrophy and neointima. IRF8 interacts with NFATc1 to suppress the nuclear translocation of NFATc1. 109 However, it competes with the acetyltransferase p300 to bind to the muscle-specific coactivator myocardin to inhibit myocardin/serum response factormediated transcription of the SMC-specific gene smooth muscle protein 22-α. 110 The interaction of IRF8 with myocardin exacerbates the formation of neointima, whereas the association between IRF9 and myocardin results in antihypertrophic effects. 111 The IRF9-PPARα interaction attenuates inflammation, insulin resistance, and hepatic steatosis. 112 However, IRF9 promotes I/R-induced hepatocyte and cardiomyocyte death via decreasing class III histone deacetylase sirtuin 1 (Sirt1) expression and increasing p53 acetylation 113, 114 ; acetylation is an indispensable event that destabilizes the interaction between p53 and its inhibitor, Mdm2, thereby enabling the p53-mediated stress response. 115 Similarly, IRF9 inhibits Sirt1 expression and reduces Sirt1 deacetylase activity in VSMCs, thereby releasing the Sirt1-mediated suppression of AP-1 transactivation and subsequently promoting cyclin D1 and matrix metallopeptidase 9 expression. 116 These reprogrammed IRF signaling events indicate that immune proteins are not solely involved in the immune response. Thus, we should endeavor to understand the effects of these proteins in CMD not only in terms of their original definition but also by their more diverse functions and molecular mechanisms.
Therefore, the reprogrammed innate immune signaling pathways, from PRRs, adaptors, and kinases to transcription factors, are essential components of signaling events in CMD. It should be noted that canonical innate immune signaling can be tightly and rigorously regulated at multiple levels by a set of negative regulators. These emerging negative regulators are also strongly associated with the pathological processes underlying CMD through their induction of conventional or nonconventional signaling pathways.
Negative Regulators of Innate Immune Signaling in CMD
Like phosphorylation, ubiquitination is reversible and deubiquitination is carried out by deubiquitinating enzymes (DUBs), such as A20 and CYLD. 117 These DUBs are negative regulators of innate immune responses and are also key factors in CMD.
A20 (also known as tumor necrosis factor AIP3 [alpha induced protein 3]) is a DUB of the ovarian tumor family and an NF-κB signaling inhibitor.
11 A20 has the ability to negatively regulate metabolic inflammation 118 ; its overexpression in adipocytes inhibits adipogenesis and lipogenesis by inhibiting NF-κB, p38, and Akt signaling, 119 and it promotes mitochondrial β-oxidation and attenuates de novo lipogenesis in HepG2 cells by an unknown mechanism. 120 In addition to conventional inhibition of inflammation and apoptosis, the beneficial effects of A20 on cardiovascular remodeling are related to suppression of the TAK1-dependent JNK/p38 signaling cascade in cardiomyocytes, TAK1-dependent Smad-2/3/4 signaling in cardiac fibroblasts, 121, 122 and PI3K/Akt/glycogen synthase kinase 3 β-dependent CREB signaling in VSMCs. 123 However, A20 deficiency promotes angiogenesis of pulmonary artery endothelial cells via stronger NF-κB activation under hypoxia. 124 These results support the cell-and stimulus-specific role of A20 in cardiovascular diseases. Therefore, A20 does not simply inhibit NF-κB signaling, it also targets mitogen-activated protein kinase, PI3K/Akt and Smad-2/3/4 signaling and even regulates mitochondrial β-oxidation and de novo lipogenesis.
CYLD is another DUB that functions as a negative regulator of NF-κB-and mitogen-activated protein kinasemediated immune and inflammatory signaling by removing lysine 63-linked (but not Lys-48-linked) polyubiquitin chains from several specific substrates, such as TRAF2, TRAF6, and TRAF7; receptor-interacting protein 1; TAK1; and NEMO. 125, 126 Therefore, liver-specific disruption of CYLD induces liver fibrosis and increases the susceptibility of mice to hepatocarcinogenesis. 127, 128 In hepatic stellate cells, CYLD interacts with histone deacetylase 7 and removes histone deacetylase 7 from the hepatocyte growth factor promoter and induces the expression of hepatocyte growth factor, which restrains hepatocellular death and hepatic fibrosis. 129 Of note, this interaction occurs independently of its deubiquitinating activity. In the cardiovascular system, CYLD disrupts the ERK, p38/AP-1, and c-Myc pathways to suppress Nrf2-mediated antioxidative capacity, thereby enhancing hypertensive ventricular remodeling and dysfunction. 130 However, the functions of CYLD in vascular remodeling are controversial. 131, 132 In addition to the DUBs above, modulators that act via competitive inhibition during innate immune response are also involved in CMD. Toll-interacting protein (Tollip), which directly associates with TLR2, TLR4, or IRAK1 to inhibit the phosphorylation and kinase activity of IRAK, 133, 134 attenuates hypertensive ventricular remodeling via directly binding to and suppressing Akt, 135 whereas the Akt inhibitory effect of Tollip contributes to aggravating injury associated with myocardial infarction 136 and cerebral I/R. 137 As mentioned above, suppressor of IKKɛ, an IKKɛ/TBK1-associated suppressor of TLR3-and retinoic acid-inducible gene I-triggered IRF3 activation, 138 directly interacts with TBK1 to inhibit the TBK1-Akt signaling pathway, thereby exerting its antihypertrophic action in both mice and rats. Moreover, injection with a lentivirus that expressed suppressor of IKKɛ protects against hypertrophic pathologies in primates, such as monkeys. 85 Studies of both rodents and primates indicate that negative regulators may be promising targets for treating CMD.
Although numerous negative regulators of innate immune signaling have been identified in recent years, few investigations have identified their influence in CMD. Our knowledge of the effects of these negative modulators on CMD is just beginning to accumulate.
Innate Immune Signaling Reprogramming: Novel and Emerging Mechanisms Underlying Cardiovascular and Metabolic Disease
Innate immunity plays a vital role in the development of CMD by regulating PRR-mediated immune and inflammatory responses. The short-term activation of innate immune and inflammatory responses is essential for tissue repair; however, long-term and high-level activation of these responses will counteract their adaptive and protective effects, leading to severe cardiometabolic dysfunction.
In terms of the impact of innate immune signaling on cardiometabolic system, only the tip of the proverbial iceberg is accessible today. The main challenge of studying innate immune signaling pathways has always been their complexity. As emphasized in the above discussion, this complexity stems from the everincreasing types and numbers of PRRs, as well as the complex manner in which their adaptors and kinases interact with each other; additionally, many negative regulators have also been implicated.
The conventional and key output of innate immune signaling activation is increased cytokine gene expression. However, the innate immune signaling not only activates/ inhibits immune cells but also affects the activities of resident cardiovascular, hepatic and fatty cells, and among others. This evidence raises questions about how innate immune signaling alters the functions of different compartments of the cardiometabolic system. Evidence indicates that PRRs, and even their downstream adaptors, kinases and transcription factors can be activated or inhibited by cardiometabolic stimuli in the parenchymal cells of cardiometabolic system, thus inducing the conventional innate immune signaling, more interestingly, causing them to undergo the non-immune signaling pathways, both of which are implicated in the pathogenesis of CMD. The immune-independent phenomenon of innate immune molecules is termed innate immune signaling reprogramming.
Innate immune signaling reprogramming reflects the signaling events that are different from these in immunity, which are novel mechanisms underlying CMD in response to various cardiometabolic stimuli, such as neurohumoral activation, hemodynamic overloading, shear stress, ischemia, hypoxia, and HFD. Innate immune signaling reprogramming has various manifestations. The innate immune receptor activated by cardiometabolic stresses can elicit nonimmune signaling. For example, angiotensin II-activated inflammasome-independent NLRP3 contributes to cardiac fibrosis via inducing ROS to augment R-Smad activation. 56 Moreover, although PRRs can be canonically activated by pathogen-associated molecular patterns to induce innate immune response, surprisingly, deficiency of certain PRRs or their downstream components also influence the balance of microbial ecology, which is essential for CMD. 139 Nevertheless, the exact bacterial species involved in this processes and the commensal-derived products that influence cardiovascular activities and wholebody metabolism remain to be determined. 4 The activation of certain innate immune signaling molecules in CMD can be regulated by nonconventional kinases. For example, ERK, not the classical IRF kinase TBK1, stimulates IRF3-Ser339 activation in angiotensin II-induced cardiac fibrosis. 140 Another interesting point is that innate immune molecules interact directly with conventional targets or with immune-independent molecules at the initiation of signal transduction, however, the final results and products are not responsible for inducing the conventional innate immune responses. 71, 82 In addition, certain transcription factors in innate immunity do not perform transcriptional functions, or, even if they function as transcription factors, they do not induce cytokine expression for immune responses. 10 Moreover, it should be noted that certain PRRs (such as NLRP3) can act as transcription factors. 57, [59] [60] [61] Therefore, the emerging role of innate immune signaling reprogramming will help us to further understand the complexity of the innate immune network, and innate immune signaling reprogramming is considered to be the key mechanism controlling CMD. Manipulation of these reprogrammed signaling pathways in animal models can dramatically alter CMD in specific ways rather than simply affecting immune responses.
Analyzing innate immune signaling reprogramming in the parenchymal cells of the cardiovascular system and metabolic organs may provide new insights into how these cells function. The integrally canonical innate immune signaling (such as the extensively studied TLR4) regulates CMD through the production of IFNs, inflammatory cytokines, and chemotactic factors; subsequently, these cytokines influence CMD by inducing inflammatory responses or contributing to CMD-related gene expression. Somewhat surprisingly, many components of conventional innate immune signaling have highly specific effects on cardiometabolic activities via reprogrammed pathways. Therefore, innate immune signaling is a sophisticated and highly complex signaling network, especially in CMD regulation. Thus, innate immune signaling reprogramming should be considered as the key mechanisms that govern the events of the cardiovascular system and metabolic organs in healthy and diseased organisms. Now, the key questions are how these reprogrammed signaling events occur at the right time and place, how they are regulated by upstream signaling events, and how they are associated with canonical PRR-mediated innate immune signaling and facilitate the specialized activities of these cells.
Conclusions and Perspective
We propose a new paradigm by which the expression of certain innate immune signaling is not only confined to immune cells for immune responses but also found in the parenchymal cells of the cardiometabolic system. The effects of these signals on cardiometabolic function are transduced via pathways that are distinct from those that active or suppress innate immune responses, leading to innate immune signaling reprogramming. Furthermore, macrophages and dendritic cells activated by pathogen-associated molecular patterns can undergo profound metabolic changes; indeed, these changes are feature of activated macrophages and dendritic cells. 141 These metabolic changes are required for biosynthesis and energy production and are also involved in signaling processes. O'Neill et al 142 termed this concept from the view of metabolism as metabolic reprogramming. Therefore, in addition to being a consequence of the level of oxygen and nutrients, metabolic reprogramming may also be driven by immune signals. 142 In other words, pathogen-associated molecular pattern-mediated metabolic reprogramming can be considered as a manifestation of innate immune signaling reprogramming. Therefore, innate immune signaling reprogramming is a conserved phenomenon that changes how we think about the biology and function of the innate immune network.
It is important to recognize that the amplification and dampening of reprogrammed innate immune signaling is likely to vary in different organs and that the primary cellular composition of an organ, the cellular and subcellular locations of innate immune signaling events, and the mediators of signaling events expressed by specialized cells will govern the overall results of the reprogramming. Therefore, activation or suppression of certain signaling events occurring at the right time and place is important for controlling CMD. Although these reprogrammed signaling events are potential targets for the treatment of CMD, substantial work is still needed to understand their precise mechanisms of regulation and to identify the functions of other immune signaling in the cardiometabolic system. Furthermore, the rapidly increasing availability of omics technologies will improve our knowledge of the role of innate immune signaling reprogramming in CMD, potentially leading to the discovery of new targets for the development of therapeutic strategies.
